Arshad M, Azad A, Chan PYK, Vigneswara V, et al. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models. Br J Cancer 2024 Apr 10. doi: 10.1038/s41416-024-02665.
PMID: 38600326